Insulet Corporation revised earnings guidance for the year ending December 31, 2024. For the year ending December 31, 2024, the company is raising its expected revenue growth to a range of 14% to 18% (previously 12% to 17%).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
177.3 USD | +0.74% | -1.56% | -18.31% |
May. 30 | Redburn Atlantic Initiates Insulet With Buy Rating, $235 Price Target | MT |
May. 29 | Insulet Insider Sold Shares Worth $596,970, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.31% | 12.42B | |
-7.16% | 178B | |
-1.23% | 107B | |
-4.86% | 67.04B | |
-4.28% | 47.24B | |
+10.32% | 44.62B | |
+8.14% | 42.5B | |
+15.76% | 29.99B | |
+15.53% | 25.22B | |
-5.88% | 24.14B |
- Stock Market
- Equities
- PODD Stock
- News Insulet Corporation
- Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024